Concluded with Distinction in Milan • Successfully Passed EU‑GMP Certification  •  Cholic Acid Project Officially Certified

Sichuan Xieli Pharmaceutical Co., Ltd.　|　October 2026

In golden October, Xieli Pharma welcomes triple celebrations at once. From returning with honors from Milan, Italy, to passing Eu-GMP certification, and on to the cholic acid project securing a provincial production license and approval number — every breakthrough is a vivid footnote to the name “Xieli-Cooperate”, and another fulfillment of the company’s founding aspiration of “quality first, innovation-driven, win-win cooperation”.

I. Honored in Milan, a Triumphant Finale

From 6 to 8 October local time, CPHI Worldwide 2026 — the world’s largest and most professional pharmaceutical industry event — was grandly held at Fiera Milano in Milan, Italy. Under the theme of “Shaping Pharma’s Future”, this year’s event brought together more than 2,900 exhibitors and over 62,000 professional visitors from 166 countries and regions, fully covering the entire industry chain — APIs, biological products, contract services, natural extracts, preparations, packaging and drug delivery. Sichuan Xieli Pharmaceutical Co., Ltd. attended as scheduled and presented at booth 3J65 its specialty APIs of natural origin, a matrix of biological enzyme products and one-stop CDMO service capabilities, bringing the “final stop” of the 2026 CPHI global exhibition series to a brilliant conclusion.

From Tokyo to Shanghai, from Seoul to Shenzhen, from Cairo to Milan, Xieli Pharma’s footprint in 2026 ran through the entire main line of the CPHI global exhibition series. At the booth, the company focused on presenting its Cholic acid series (Ursodeoxycholic Acid, Cholic Acid, Chenodeoxycholic Acid, etc.), Citrus Flavonoid series, oncology and high-barrier specialty products, biological enzyme series and health product raw material portfolio, and showcased multiple international certifications including the EU CEP certificate, US FDA inspection qualification, EU GMP and Japanese GMP. During the three days of in-depth exchanges, the international trade, technical and regulatory teams were on hand throughout, reaching a number of preliminary cooperation intentions with partners from Europe, the Americas, the Middle East and Asia-Pacific on topics such as capacity assurance, impurity control, CEP/DMF/ANDA international registration and customized development.

To date, the company has obtained 6 CEP certificates in total, the plant receives more than 80 GMP audits annually on average, and our products and services cover more than 100 countries and regions worldwide with over 400 global partners. The triumphant conclusion in Milan constitutes a powerful brand statement for Xieli on the global stage.

II. Celebrate Successful EU-GMP Certification

Quality is Xieli’s passport to the world. The company has passed multiple international certifications including US FDA on-site inspection, EU GMP and Japanese GMP; its core products hold international registration qualifications such as the EU CEP certificate and US DMF; and in July this year it won the EcoVadis Bronze sustainability rating and passed a PSCI on-site audit, writing “Compliance, Green and Sustainable” into its new commitment to customers worldwide.

EU-GMP certification is the gold standard of European pharmaceutical quality management. From establishing the documentation system to upgrading on‑site hardware, from self‑inspections and corrective actions to the official inspection, the Xieli team, with rigor and dedication, has built a quality management system benchmarked against international standards. On this celebratory occasion, we celebrate the Eu-GMP certification every success — this is not only the triumphant conclusion of a high-standard inspection, but also another solid step for Xieli products into Europe’s regulated market, opening a new door for its global layout.

III. Cholic Acid Project Officially Certified

While steadily expanding in plant-extract pharmaceuticals, Xieli Pharma has also reported good news in the field of animal nutrition and feed additives.

On 28 July 2026, the Sichuan Provincial Department of Agriculture and Rural Affairs officially issued to the company the Feed Additive Bile Acid Production License and the Mixed Feed Additive Production License (Curcumin), marking authoritative recognition of the cholic acid project’s industrialization capability in the feed additive sector.

On 10 September 2026, the Sichuan Provincial Department of Agriculture and Rural Affairs brought more good news: the company’s feed additive bile acid obtained an approval number — Chuan Si Tian No. 2026T01025. From project initiation to key‑challenge tackling, from trial production to certification, the Cholic Acid project embodies the painstaking efforts of numerous Xieli team members and has now officially borne fruit.

The approval of both licenses together with the granting of the approval number is an important step in expanding Xieli Pharma’s product line and another milestone in the company’s continued deep cultivation of the dual tracks of “APIs + Animal Nutrition”, providing safer and more efficient green additive solutions for the downstream feed and breeding industries.

Epilogue: Forging Ahead, Together

Honors earned in Milan belong to Xieli; successful on‑site EU‑GMP certification belongs to Xieli; certification for the cholic acid project also belongs to Xieli. The name “Xieli” stands not only as our corporate identity, but also as the foundational spirit behind every step of our journey.

Looking to the future, Xieli Pharma will remain true to its original aspiration, build on its core technologies in natural extraction and bio-manufacturing, and continue to improve the full-chain system of “R&D – Registration – Production – Supply”, delivering high-quality plant-extract APIs, biological enzymes and animal nutrition products. Together with peers in global pharmaceuticals and animal nutrition, we will jointly promote the high-quality development of the health industry.